GAMMA Investing LLC Has $205,000 Position in Charles River Laboratories International, Inc. (NYSE:CRL)

GAMMA Investing LLC raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 22.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,041 shares of the medical research company’s stock after purchasing an additional 192 shares during the quarter. GAMMA Investing LLC’s holdings in Charles River Laboratories International were worth $205,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Charles River Laboratories International by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 6,046,467 shares of the medical research company’s stock worth $1,638,290,000 after buying an additional 66,161 shares during the period. Kayne Anderson Rudnick Investment Management LLC lifted its position in Charles River Laboratories International by 1.7% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company’s stock worth $394,359,000 after acquiring an additional 31,359 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in shares of Charles River Laboratories International by 3.1% during the first quarter. Clearbridge Investments LLC now owns 1,513,138 shares of the medical research company’s stock worth $409,985,000 after acquiring an additional 45,079 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of Charles River Laboratories International by 11.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,251,618 shares of the medical research company’s stock valued at $258,559,000 after purchasing an additional 132,802 shares during the last quarter. Finally, Meritage Group LP increased its position in Charles River Laboratories International by 2.3% during the 1st quarter. Meritage Group LP now owns 1,182,268 shares of the medical research company’s stock worth $320,336,000 after buying an additional 26,892 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $192.97 on Friday. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The company has a quick ratio of 1.21, a current ratio of 1.58 and a debt-to-equity ratio of 0.65. The stock’s 50-day simple moving average is $198.80 and its 200 day simple moving average is $216.62. The firm has a market capitalization of $9.96 billion, a PE ratio of 23.11, a price-to-earnings-growth ratio of 5.11 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.41. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has approved a share buyback plan on Wednesday, August 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CRL. Citigroup cut shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their target price for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Argus restated a “hold” rating on shares of Charles River Laboratories International in a research report on Friday, June 28th. Bank of America cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $250.00 to $215.00 in a report on Wednesday, October 2nd. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Robert W. Baird dropped their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, September 20th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and a consensus target price of $217.33.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).